Translational PK–PD model for in vivo CAR‐T‐cell therapy delivered using CAR mRNA‐loaded polymeric nanoparticle vector
Clinical and Translational Science · 2024-12 · 17 (12)
DOI: 10.1111/cts.70101 ↗At a glance
Journal article in Clinical and Translational Science, published online on 2024-12-18. Written by Se Jin Kim and 2 co-authors. Institution: Oncology Cell Therapy and Therapeutic Area Unit, Cell Therapy Clinical Pharmacology and Modeling, Precision and Translational Medicine, Takeda Pharma…. Major MEDLINE topics: Nanoparticles, RNA, Messenger, Immunotherapy, Adoptive, Receptors, Chimeric Antigen. Cited 20 times so far (Crossref); 46 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Takeda Development Center Americas, Inc.
Abstract (original language)
Autologous chimeric antigen receptor (CAR) T‐cell therapy has demonstrated remarkable response rates, yet its widespread implementation is hindered by logistical, financial, and physical constraints. Additionally, challenges such as poor persistence and allorejection are associated with allogeneic cell therapies. An innovative approach involves in vivo transduction of endogenous T‐cells through the administration of CAR mRNA encapsulated in polymeric nanoparticles (NPs), resulting in transient CAR surface expression on circulating T‐cells. This method presents a promising alternative, although the dose–exposure–response relationship of in vivo CAR‐Ts remains poorly elucidated. The transient nature of CAR expression may necessitate repeated dosing, potentially introducing additional hurdles like cost and patient compliance. To address this issue, we have devised a translational pharmacokinetic–pharmacodynamic (PK–PD) model that characterizes the transient surface CAR expression following mRNA‐encapsulated NP administration, leveraging in vitro and in vivo data alongside critical binding kinetic parameters sourced from literature. Our model adequately captures the transient surface CAR expression in both settings, while incorporating known physiological parameter values and exhibiting precise estimation of unknown parameters (coefficient of variation < 30%). Global sensitivity analyses underscore the significance of intracellular mRNA stability, highlighting the sensitivity of parameters linked to free intracellular mRNA concentration. Model‐based simulations indicate that optimizing dose and dosing frequency can achieve sustained CAR expression, despite the transient protein expression characteristic of mRNA‐based therapies. This mechanistic PK–PD model holds potential for integration into physiologically‐based pharmacokinetic models, facilitating the translation of in vivo CAR‐T‐cell therapies from preclinical studies to human applications.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Oncology Cell Therapy and Therapeutic Area Unit, Cell Therapy Clinical Pharmacology and Modeling, Precision and Translational Medicine, Takeda Pharmaceuticals, Cambridge, Massachusetts, USA.
- Department of Pharmaceutical Sciences, University at Buffalo, SUNY, Buffalo, New York, USA.
ORCID profiles: Se Jin Kim, Ganesh M Mugundu, Aman P Singh
Funding
- Takeda Development Center Americas, Inc
Cite
APA
Kim, S. J., Mugundu, G. M., & Singh, A. P. (2024). Translational PK–PD model for in vivo CAR‐T‐cell therapy delivered using CAR mRNA‐loaded polymeric nanoparticle vector. Clinical and Translational Science, 17(12). https://doi.org/10.1111/cts.70101
Vancouver
Kim SJ, Mugundu GM, Singh AP. Translational PK–PD model for in vivo CAR‐T‐cell therapy delivered using CAR mRNA‐loaded polymeric nanoparticle vector. Clinical and Translational Science. 2024;17(12). doi:10.1111/cts.70101
BibTeX
@article{Kim2024,
author = {Kim, Se Jin and Mugundu, Ganesh M and Singh, Aman P},
title = {Translational PK–PD model for in vivo CAR‐T‐cell therapy delivered using CAR mRNA‐loaded polymeric nanoparticle vector},
journal = {Clinical and Translational Science},
year = {2024},
volume = {17},
number = {12},
doi = {10.1111/cts.70101}
}
EUVIMED